New drug could cut Blood-Letting for rare blood cancer patients
NCT ID NCT07429266
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study tests a new drug called sapablursen in 250 people with polycythemia vera, a condition where the body makes too many red blood cells. The drug is added to standard treatment to see if it can reduce the need for regular blood removal (phlebotomy). Participants will receive either sapablursen or a placebo for up to 156 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Regis Clinical Research LLC.
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.